Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases, particularly those with limited or no therapeutic options. Founded in 2003 and headquartered in Dublin, Ireland, with significant operational hubs in the United States (Palo Alto, Philadelphia, Carlsbad) and Europe, the company focuses on identifying, developing, and commercializing differentiated products that address significant unmet medical needs.
The company's core mission revolves on "redefining possibilities" for patients. Jazz Pharmaceuticals operates a vertically integrated business model, managing everything from early-stage research and development (R&D) to manufacturing and global commercialization. The company has grown significantly through a combination of organic R&D and strategic acquisitions, most notably the acquisition of GW Pharmaceuticals in 2021, which established Jazz as a leader in cannabinoid-based neuroscience.
Therapeutic Focus and Commercial Portfolio
Jazz Pharmaceuticals concentrates its efforts on two primary therapeutic areas: Neuroscience and Oncology.
1. Neuroscience
Jazz is a recognized global leader in sleep medicine and has a rapidly growing footprint in the treatment of rare, debilitating epilepsies.
Sleep Medicine
The company has revolutionized the treatment of sleep disorders, particularly Narcolepsy and Idiopathic Hypersomnia (IH).
* Xywav? (calcium, magnesium, potassium, and sodium oxybates): An oral solution approved for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy, and for idiopathic hypersomnia in adults. It is a lower-sodium oxybate option designed to reduce the long-term sodium burden on patients compared to its predecessor.
* Xyrem? (sodium oxybate): The company's first major product, an oral solution indicated for the treatment of cataplexy or EDS in narcolepsy. It remains a cornerstone therapy in sleep medicine.
Epilepsy
Through its acquisition of GW Pharmaceuticals, Jazz expanded into the epilepsy space with a focus on plant-derived cannabinoid therapeutics.
* Epidiolex? / Epidyolex? (cannabidiol): The first and only FDA-approved prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD). It is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and tuberous sclerosis complex (TSC) in patients 1 year of age and older.
2. Oncology
Jazz?s oncology portfolio focuses on difficult-to-treat hematologic malignancies (blood cancers) and solid tumors. The company specializes in identifying compounds for niche indications where standard treatments have failed or are unavailable.
Zepzelca? (lurbinectedin): An alkylating drug used to treat adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression on or after platinum-based chemotherapy.
Rylaze? / Enrylaze? (asparaginase erwinia chrysanthemi (recombinant)-rywn): A recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). It addresses a critical shortage of erwinia asparaginase treatments for patients hypersensitive to E. coli-derived asparaginase.
Vyxeos? (daunorubicin and cytarabine liposome for injection): A liposomal combination of two standard chemotherapy drugs (daunorubicin and cytarabine) indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Defitelio? (defibrotide sodium): The first and only FDA-approved treatment for adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
Research and Development (Pipeline)
Jazz Pharmaceuticals invests heavily in a robust pipeline to sustain long-term growth. Their R&D strategy involves both internal discovery and external partnerships.
Zanidatamab: A key late-stage asset. It is a bispecific antibody targeting HER2, being investigated for the treatment of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA).
Targeted Oncology: The company is developing pan-RAF inhibitors (e.g., JZP815) that target specific mutations in the MAPK pathway, relevant for various solid tumors.
Next-Generation Neuroscience: Continued research into movement disorders and PTSD, leveraging their expertise in vesicular monoamine transporter 2 (VMAT2) inhibitors and other mechanisms.
Corporate Responsibility and Patient Support
Jazz Pharmaceuticals emphasizes a patient-centric culture. Beyond drug development, they offer significant support services:
JazzCares: A support program in the U.S. that helps patients access their prescribed medications. This includes benefits verification, prior authorization support, and financial assistance programs for eligible uninsured or underinsured patients.
REMS Programs: Due to the potent nature of some of their sleep medicines (specifically oxybates), Jazz manages strict Risk Evaluation and Mitigation Strategies (REMS) to ensure safe distribution and prevent misuse.
Company Snapshot
Legal Name: Jazz Pharmaceuticals plc
Ticker Symbol: NASDAQ: JAZZ
Headquarters: Dublin, Ireland
Founded: 2003 (in California; reincorporated in Ireland following a merger in 2012)
